



Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

September 14, 2026

Company to host a virtual event today at 8:00 a.m. ET

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- [Cullinan Therapeutics, Inc.](#) (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that it will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET to discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy presented in Presidential Symposium 2 at the International Association for the Study of Lung Cancer's (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Virtual Event Details

Cullinan Therapeutics will host a virtual event for analysts and institutional investors today at 8:00 a.m. ET. Participants from Cullinan Therapeutics include Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, MD, MBA, Chief Medical Officer.

A live webcast will be available via the events page of Cullinan Therapeutics' investor relations website at <https://investors.cullinantherapeutics.com/events>. A replay will be archived on the website following the event.

About Cullinan Therapeutics

[Cullinan Therapeutics, Inc.](#) (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at <https://cullinantherapeutics.com/>, and follow Cullinan on [LinkedIn](#) and [X](#).

Contacts

Cullinan Therapeutics

Investors

Nick Smith

+1 401.241.3516

Nsmith@cullinantx.com

Media

Rose Weldon

+1 215.801.7644

Rweldon@cullinantx.com